The requested news item does not exist. Please return to News
Greater Boston is a leading global industry cluster with Cambridge at its core
Among the emerging clusters, Singapore is best poised to increase its high-tech research presence based on its strong intellectual property laws, stable and industry-supportive political structures and mature business environment that make the island-nation an ideal launching pad into other Asia-Pacific markets.
In China, the government’s five-year plan includes programs designed to stimulate growth in sectors such as biotechnology. These investments are paying off with several big pharmaceutical players expanding beyond manufacturing facilities by opening research operations in the country, the intellectual property risks being outweighed by the sheer size of the market.
In India, companies have already made significant headway in manufacturing generic versions of expensive drugs, showing they have the local skills to be globally competitive. The government hopes to expand beyond the country’s strong generic and contract manufacturing presence into biosimilars and contract research. The Indian government has even created competitive tax concessions to encourage R&D.
In Latin America, several countries are emerging as competitive clusters in agricultural biotechnology; infrastructure built around this sector could serve as a springboard into further developments in human-use drugs and biotechnology.
United States & Europe Remain Prominent Global PlayersThough emerging clusters are playing a more prominent role in the global life sciences industry, Europe, the United States and Japan are undoubtedly still world leaders in the sector, especially in the R&D aspects of the value chain.
“World-class research universities, sustained venture capital and other investments coupled with the supporting infrastructure within these mature clusters continues to fuel innovation in the United States and Europe,” said Charles Tillet, National Director, Corporate Solutions, and head of EMEA’s Life Sciences practice. “Requirements from small start-ups and the occasional right-sizing or re-locating of headquarter operations remain prevalent in established clusters in the United States and Europe.”
The analysis shows real estate activity is most prominent in cornerstone locales, such as Boston, the Bay Area, the New York / New Jersey corridor, San Diego, Seattle, Philadelphia, the United Kingdom, France, Switzerland and Germany, and Jones Lang LaSalle predicts these clusters will remain leaders in site selection for headquarter operations and R&D functionalities.
To download a copy of the full report, click here.
Jones Lang LaSalle has a team of real estate experts dedicated to helping Life Sciences companies optimize their real estate portfolios. We provide a comprehensive range of facilities management services covering 70 million square feet of space including research, manufacturing and commercial sites with more than 1,000 staff on-site. As the life sciences industry changes, our experts continue to evolve to accommodate the changing environment that companies face. Our industry leading full-service platform includes: integrated facilities management, engineering and operations, energy and sustainability, transaction management, lease administration and project management.
+1 312 228 2797
+1 617 531 4122